Recently announced development deal with Becton Dickinson for diagnostic test for Alzheimer's.
Potential $500,000,000 annual revenues.
Currently trading under a dime.
Announced orphan indication yesterday.
Read the Yahoo news.
License agreement with Becton Dickinson for its diagnostic test to detect early stage Alzheimer's will move the share price above .50. Stay tuned.
Chill order lifted today. Substantial upside.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's advisory board.